If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

 

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 219.00
Bid: 218.00
Ask: 219.00
Change: -3.00 (-1.35%)
Spread: 1.00 (0.459%)
Open: 220.50
High: 221.50
Low: 218.00
Prev. Close: 222.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PureTech Health investment Vor Biopharma raises $42m in funding round

Thu, 14th Feb 2019 12:28

(Sharecast News) - Advanced biopharmaceutical company PureTech Health noted on Thursday that its affiliate, Vor Biopharma, had raised $42m in a Series A financing round.The London-listed firm said the round was led by 5AM Ventures and RA Capital Management, with participation from Johnson & Johnson Innovation (JJDC), Novartis Institutes for BioMedical Research (NIBR), Osage University Partners, and itself as a co-founder.It said the proceeds from the financing would be used to advance Vor's lead engineered hematopoietic stem cell (HSC)-based candidate for the treatment of acute myeloid leukaemia (AML) towards the clinic, and to further build its pipeline to treat hematologic malignancies.PureTech described Vor's approach as being designed to target cancer cells while sparing healthy blood cells, adding that it had the potential to expand the reach of existing targeted immunotherapies to a broad range of patient populations and haematological malignancies, including AML where there was a "significant need" for more-effective, less-toxic treatment options.Vor's engineered HSC technology platform was designed to address the "fundamental limitations" of the highly potent immunotherapies currently available, including antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T cells, it explained."Vor's approach is designed to overcome a major limitation of some of the most powerful cancer treatments and to offer a novel therapeutic approach for patients who currently have very few treatment options and poor prognosis," said PureTech Health chief scientific officer Joseph Bolen."Funding from this impressive syndicate of financial and strategic investors provides an important endorsement of this unique platform and brings us closer to our goal of addressing the tremendous need for new cancer therapies."PureTech Health was one of the founding partners in Vor Biopharma, and held around 30.2% of its equity on a diluted basis following the financing round.
More News
25 Apr 2024 10:07

Puretech Health operating losses narrow in 'landmark year'

(Sharecast News) - Biotechnology company Puretech Health said on Thursday that 2023 had been "a landmark year" for the group, making "strong strategic and clinical progress".

Read more
25 Apr 2024 09:59

PureTech touts "momentum" as grants shrivel but annual loss narrows

(Alliance News) - PureTech Health PLC on Thursday maintained an optimistic outlook for the year ahead, despite seeing annual revenue fall.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:43

LONDON BRIEFING: Miner Anglo American eyes rival BHP takeover

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
18 Apr 2024 14:17

UK earnings, trading statements calendar - next 7 days

Friday 19 April 
888 Holdings PLCTrading Statement
Man Group PLCTrading Statement
Monday 22 April 
Brave Bison Group PLCFull Year Results
Elixirr International PLCFull Year Results
Frenkel Topping Group PLCFull Year Results
Mobico Group PLCFull Year Results
South32 LtdQ3 Results
Ten Lifestyle Group PLCHalf Year Results
Tuesday 23 April 
Alliance Pharma PLCFull Year Results
Alphawave IP Group PLCFull Year Results
Anglo American PLCTrading Statement
ASA International Group PLCFull Year Results
Associated British Foods PLCHalf Year Results
Eleco PLCFull Year Results
GB Group PLCTrading Statement
Jupiter Fund Management PLCTrading Statement
Maintel Holdings PLCFull Year Results
Property Franchise Group PLCFull Year Results
Taylor Wimpey PLCTrading Statement
tinyBuild IncFull Year Results
Trellus Health PLCFull Year Results
Wednesday 24 April 
1Spatial PLCFull Year Results
abrdn PLCTrading Statement
Ecora Resources PLCTrading Statement
Fresnillo PLCTrading Statement
Lloyds Banking Group PLCQ1 Results
Nichols PLCTrading Statement
PensionBee Group PLCFirst Quarter Results
PZ Cussons PLCTrading Statement
Reckitt Benckiser Group PLCTrading Statement
Sanderson Design Group PLCFull Year Results
Serica Energy PLCFull Year Results
Star Energy Group PLCFull Year Results
Tortilla Mexican Grill PLCFull Year Results
Tracsis PLCHalf Year Results
Warpaint London PLCFull Year Results
Thursday 25 April 
Aquila European Renewables PLCFull Year Results
Argo Blockchain PLCFull Year Results
AstraZeneca PLCQ1 Results
Barclays PLCQ1 Results
Checkit PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Destiny Pharma PLCFull Year Results
Hikma Pharmaceuticals PLCTrading Statement
Focusrite PLCHalf Year Results
Ibstock PLCTrading Statement
Inchcape PLCTrading Statement
J Sainsbury PLCFull Year Results
London Stock Exchange Group PLCQ1 Results
Persimmon PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
PureTech Health PLCFull Year Results
Relx PLCTrading Statement
Renewi PLCTrading Statement
Schroders PLCQ1 Results
Skillcast Group PLCFull Year Results
Travis Perkins PLCTrading Statement
Trifast PLCTrading Statement
Unilever PLCQ1 Results
WAG Payment Solutions PLCTrading Statement
Weir Group PLCTrading Statement
WH Smith PLCHalf Year Results
WPP PLCTrading Statement
Zinc Media Group PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
16 Apr 2024 21:57

EARNINGS AND TRADING: J Smart boosts revenue, Tertiary starts drilling

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
11 Apr 2024 13:01

US FDA hands fast track to PureTech head and neck cancer treatment

(Alliance News) - PureTech Health PLC on Thursday said that its LYT-200 cancer treatment has received a significant endorsement from the US drugs regulator.

Read more
9 Apr 2024 11:33

PureTech Health CEO Zohar moves to head-up portfolio firm Seaport

(Alliance News) - PureTech Health PLC on Tuesday said its founding chief executive officer, Daphne Zohar, will shift to become CEO of Seaport Therapeutics, a biopharmaceutical company founded by PureTech.

Read more
9 Apr 2024 07:48

PureTech founder steps down as CEO to lead SeaPort spin-off

(Sharecast News) - Clinical-stage biotherapeutics group PureTech has announced that its founding chief executive is to step down to lead SeaPort Therapeutics, a PureTech company she founded that has just raised $100m in Series A financing.

Read more
19 Mar 2024 16:57

LONDON MARKET CLOSE: European large-caps rise on eve of Fed decision

(Alliance News) - Blue-chip stock prices in Europe closed higher on Tuesday, showing little signs of nerves ahead of Wednesday's Federal Reserve decision and UK inflation reading.

Read more
19 Mar 2024 11:16

PureTech shares jump on USD100 million tender offer proposal

(Alliance News) - PureTech Health PLC on Tuesday said it plans to return USD100 million to shareholders with a tender offer, starting after it publishes its annual report in April.

Read more
19 Mar 2024 09:46

Puretech Health proposes $100m capital return

(Sharecast News) - Biotherapeutics company PureTech Health has proposed a capital return of $100.0m to its shareholders by way of a tender offer.

Read more
13 Mar 2024 12:27

PureTech Health celebrates drug designation for LYT-200 from US FDA

(Alliance News) - PureTech Health PLC on Wednesday touted the efficacy of its acute myeloid leukaemia therapy, after securing a regulatory designation from the US Food & Drug Administration.

Read more
27 Feb 2024 11:28

PureTech notes positive results from Shionogi's EndeavorRx ADHD trial

(Alliance News) - PureTech Health PLC on Tuesday noted that its founded entity, Akili Inc, has announced positive results from a phase 3 clinical trial of EndeavorRx for children with attention deficit hyperactivity disorder in Japan.

Read more
20 Dec 2023 09:53

PureTech makes strong progress, expects "multiple catalysts" next year

(Alliance News) - PureTech Health PLC on Wednesday said it made "strong strategic and clinical progress" in 2023, and predicted "a productive and exciting" tear to come.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.